Loading…
Ocugen, Inc. is projected to rise to $1.23 by 2027, a 0% move from its current price of $1.23. OCGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $1.19 | $1.23 | $1.27 | 0.00% |
| Aug 4 | $1.18 | $1.23 | $1.28 | 0.00% |
| Aug 5 | $1.17 | $1.23 | $1.30 | 0.00% |
| Aug 6 | $1.16 | $1.23 | $1.31 | 0.00% |
| Aug 7 | $1.15 | $1.23 | $1.32 | 0.00% |
| Aug 8 | $1.14 | $1.23 | $1.33 | -0.01% |
| Aug 9 | $1.13 | $1.23 | $1.33 | -0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.13 | $1.23 | $1.33 | -0.01% |
| Week 2 | $1.10 | $1.23 | $1.38 | -0.01% |
| Week 3 | $1.07 | $1.23 | $1.41 | -0.02% |
| Week 4 | $1.05 | $1.23 | $1.45 | -0.02% |
| Week 5 | $1.03 | $1.23 | $1.47 | -0.03% |
| Week 6 | $1.01 | $1.23 | $1.50 | -0.04% |
| Week 7 | $0.9925 | $1.23 | $1.52 | -0.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. Its pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis.
It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc.
for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Ocugen, Inc. (OCGN) is a healthcare company with a current price of $1.27 and a market cap of $429.92M, ranking 3093 by market size. The stock sits in a context of a bearish to neutral near term but shows a clear long‑term bullish trajectory in the forecast.
The near‑term price path points to a cautious start, while the multi‑year outlook projects rising averages and higher upper‑bound scenarios into 2030 and beyond, with a potential upside toward the mid‑$ to high-$ range by 2050.
A major floor 28.2% below — a decisive break under it would weaken the trend.
The nearest floor, 3.3% below — buyers have tended to step in here.
The nearest ceiling, 35.8% above — a clean break opens room to run.
A major ceiling 61.8% above — clearing it would confirm fresh momentum.
Key OCGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OCGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.24 | Sell | $1.24 | Sell |
| MA 10 | $1.26 | Sell | $1.27 | Sell |
| MA 20 | $1.35 | Sell | $1.31 | Sell |
| MA 50 | $1.35 | Sell | $1.38 | Sell |
| MA 100 | $1.58 | Sell | $1.46 | Sell |
| MA 200 | $1.53 | Sell | $1.45 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.91 | Neutral |
| Stoch RSI (14) | 41.60 | Neutral |
| CCI (20) | -86.85 | Neutral |
| Williams %R (14) | -83.33 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -13.99 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 16.67 | Buy |
| TRIX (15) | -0.31 | Sell |
| Awesome (5,34) | -0.12 | Sell |
| Ultimate (7,14,28) | 38.34 | Neutral |
| Momentum (10) | -0.13 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 1.22 | Buy |
| ADX (14) | 19.21 | Neutral |
| ATR (14) | 0.04 | Info |
The 30‑day technical picture is bearish with an RSI of 40. The 50‑day simple moving average is $1.37 and the 200‑day simple moving average is $1.54, signaling a softer trend relative to recent price action. Support sits at $1.18 and resistance at $1.67, framing a modest range around the current level.
The 30‑day range is from $1.05 to $1.54, indicating limited upward momentum in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.18 | $1.23 | $1.52 | 0% | Neutral | |
| $0.9732 | $1.23 | $1.66 | 0% | Neutral | |
| $1.06 | $1.39 | $1.94 | +13% | Neutral | |
| $1.14 | $1.54 | $2.23 | +25% | Bullish | |
| $1.26 | $1.74 | $2.59 | +41% | Bullish | |
| $1.33 | $1.86 | $2.84 | +52% | Bullish | |
| $1.20 | $1.72 | $2.68 | +40% | Bullish | |
| $1.22 | $1.79 | $2.83 | +45% | Bullish | |
| $1.28 | $1.90 | $3.06 | +54% | Bullish | |
| $1.43 | $2.17 | $3.56 | +77% | Bullish | |
| $1.60 | $2.63 | $4.60 | +114% | Bullish | |
| $2.81 | $5.26 | $10.16 | +328% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.18 | $1.23 | $1.43 | +0.00% |
| September 2026 | $1.01 | $1.20 | $1.46 | -2.76% |
| October 2026 | $1.03 | $1.23 | $1.52 | +2.76% |
| November 2026 | $1.01 | $1.21 | $1.51 | -1.44% |
| December 2026 | $0.9964 | $1.21 | $1.52 | -0.40% |
Click any year to see its month-by-month OCGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, OCGN is projected to trade between $1.18 and $1.52, averaging $1.23 — a potential gain of 0% from today's $1.23. Price action looks broadly range-bound.
Ocugen, Inc.'s 2027 outlook centres on $1.23, within a $0.9732 to $1.66 range. That is up 0% on the projected 2026 average. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, OCGN could reach as high as $1.94, with a base case around $1.39 and support toward $1.06 — roughly +13% from $1.23. Price action looks broadly range-bound.
Expect OCGN to range from $1.14 to $2.23 through 2029. The $1.54 average target implies a +25% move from current prices. That is up +11% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The OCGN price prediction for 2030 points to an average of $1.74 (low $1.26, high $2.59) — a potential gain of +41% on today's $1.23. Momentum favours further upside here.
In 2031, OCGN is projected to trade between $1.33 and $2.84, averaging $1.86 — a potential gain of +52% from today's $1.23. That is up +7% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Ocugen, Inc.'s 2032 outlook centres on $1.72, within a $1.20 to $2.68 range. That is -8% versus the projected 2031 average. That marks a +40% change versus current levels. Momentum favours further upside here.
By 2033, OCGN could reach as high as $2.83, with a base case around $1.79 and support toward $1.22 — roughly +45% from $1.23. Buyers look set to stay in control over this stretch.
Expect OCGN to range from $1.28 to $3.06 through 2034. The $1.90 average target implies a +54% move from current prices. That is up +6% on the projected 2033 average. Momentum favours further upside here.
The OCGN price prediction for 2035 points to an average of $2.17 (low $1.43, high $3.56) — a potential gain of +77% on today's $1.23. Buyers look set to stay in control over this stretch.
In 2040, OCGN is projected to trade between $1.60 and $4.60, averaging $2.63 — a potential gain of +114% from today's $1.23. That is up +21% on the projected 2035 average. Momentum favours further upside here.
Ocugen, Inc.'s 2050 outlook centres on $5.26, within a $2.81 to $10.16 range. That is up +100% on the projected 2040 average. That marks a +328% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in OCGN today (≈ 813.00813 OCGN) could be worth
$4,279.74
+$3,279.74 (+328%) by 2050 · US Dollar
Based on the average projected OCGN price of $5.26 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OCGNwould be worth at today's price.
$1,000 invested in OCGN on Jul 31, 2025 (≈ 970.873813 OCGN) would be worth
$1,194.17
+$194.17 (+19.4%) today · 1.19× · US Dollar
Based on a OCGN entry price of $1.03 vs. today's $1.23.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.21 | $1,016.53 | +1.7% |
| 1 month ago | $1.48 | $831.08 | -16.9% |
| 3 months ago | $1.8 | $683.33 | -31.7% |
| 6 months ago | $1.43 | $860.14 | -14.0% |
| 1 year ago | $1.03 | $1,194.17 | +19.4% |
| All time (5.0y) ago | $7.05 | $174.47 | -82.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OCGN forecast.
Our base-case forecast reaches $2.50 around 2040.
Implied market cap at $2.50: $846.3M
The multi‑year forecast shows a path from neutral to bullish momentum over time. For 2026 the average price is $1.27 with a min of $1.18 and a max of $1.58, and ROI of 0, indicating a flat near‑term outlook. In 2027 the average is $1.26 (min $0.9983, max $1.69) with ROI of -0.7, still Neutral.
By 2030 the average rises to $1.70 with a min of $1.25 and a max of $2.51, and ROI of 34.2, signaling a bullish long‑term shift. The trajectory continues higher through 2031–2035, culminating in 2035 with an average of $2.05, a min of $1.37, a max of $3.31, and ROI of 61.3. From 2040 onward, averages climb to $2.42 (ROI 90.5) and by 2050 the forecast shows an average of $4.88, a min of $2.67, a max of $9.26, and ROI of 284.6, with the sentiment bullish.
These figures point to meaningful upside potential over the long term, tempered by near‑term uncertainty and volatility.
Tap a question to reveal the answer.
The 2026 forecast shows min $1.18, avg $1.27, max $1.58 with ROI 0 and sentiment Neutral.
Near term the forecast is Neutral to Bearish with current sentiment Bearish, but the longer‑term view turns Bullish starting around 2030, with higher avg prices and upside potential by 2040–2050.
Yes. The forecast max price reaches $2.17 in 2029 and rises to $2.51 in 2030, with higher upside in later years.
2035 forecast shows avg $2.05, min $1.37, max $3.31, ROI 61.3, with bullish sentiment.
The 2050 forecast shows avg $4.88, min $2.67, max $9.26, ROI 284.6, with bullish sentiment.
Ocugen, Inc. Community Discussion
0Share your Ocugen, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.